Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc for Idiopathic Inflammatory Myopathies
NCT07668505Phase 4Not yet recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Sep 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of maraviroc in idiopathic inflammatory myopathy (IIM), sponsored by The Chinese University of Hong Kong. Primary endpoint: IMACS definition of minimal clinical improvement (DOI) at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
maraviroc
03
Conditions
idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07668505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668505.